Oral GLP‑1 approvals accelerate

The Food and Drug Administration has approved Foundayo, Eli Lilly’s once-daily obesity pill, adding a new oral option to the prescription weight-loss market. (fda.gov) Foundayo is the brand name for orforglipron, a glucagon-like peptide-1 receptor agonist in tablet form for adults with obesity, or overweight with at least one weight-related condition. The agency approved it on April 1, 2026, 50 days after filing and 294 days before its Prescription Drug User Fee Act target date of January 20, 2027. (fda.gov) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and eat less; most of the big sellers so far have been injections. The Food and Drug Administration said Foundayo is taken once daily by mouth and does not need to be taken on an empty stomach. (fda.gov; medical.lilly.com) The approval lands two weeks after the Food and Drug Administration cleared Wegovy HD, a new 7.2 milligram higher-dose version of Novo Nordisk’s semaglutide injection, on March 19, 2026. The agency said that decision came 54 days after filing under the same Commissioner’s National Priority Voucher pilot program. (fda.gov) Wegovy HD gives Novo Nordisk a higher-dose injectable as Lilly brings in a pill, tightening a contest that had already centered on convenience, weight-loss results, and supply. Novo Nordisk said Wegovy HD was available nationwide as of April 7, 2026. (fda.gov; novonordisk-us.com) The Food and Drug Administration said Foundayo should start at 0.8 milligrams, then rise to 2.5 milligrams after at least 30 days and to 5.5 milligrams after another 30 days, with optional increases up to 17.2 milligrams based on response and tolerability. The agency described the drug as a glucagon-like peptide-1 receptor partial agonist. (fda.gov) Amazon is moving quickly into the launch. Its press center said on April 9, 2026, that Amazon Pharmacy would offer Foundayo through same-day delivery, and Business Wire said the service covers nearly 3,000 cities and towns now and is planned to expand to nearly 4,500 by year end. (aboutamazon.com; businesswire.com) Pricing is also part of the rollout. Lilly’s savings page says eligible commercially insured patients can pay as little as $25 a month, and Amazon’s release said insured pricing starts at about $1 a day while cash-pay pricing starts at $149 a month. (foundayo.lilly.com; businesswire.com) The efficacy race is still moving underneath these launches. Novo Nordisk said on February 23, 2026, that its experimental CagriSema produced 23.0% weight loss after 84 weeks in REDEFINE 4, but missed the trial’s primary goal of showing noninferiority to tirzepatide 15 milligrams, which posted 25.5% in the same analysis. (ntb.no) That leaves the market with two separate shifts in spring 2026: faster Food and Drug Administration reviews for obesity drugs, and more competition over how patients get them. One company now has a newly approved daily pill, and the other has a newly approved stronger shot. (fda.gov; fda.gov)